Skip to content
Review Open access

Deferring prostate biopsy after magnetic resonance imaging: evidence-graded thresholds for men with suspected prostate cancer – a narrative review

Oct 2026 · Clinical Standard · 0 citations · 27 references

Abstract

Magnetic resonance imaging (MRI) before biopsy has replaced systematic transrectal ultrasound-guided sampling as the first diagnostic step for men with suspected prostate cancer; the open question is which men can safely forgo biopsy after imaging. This narrative review synthesised randomised trials, paired diagnostic studies, screening trials and meta-analyses identified from 441 unique PubMed records searched to September 2026 (45 sources cited) to derive evidence-graded thresholds for deferring biopsy. A non-suspicious MRI (Prostate Imaging Reporting and Data System [PI-RADS] score 1–2) had a pooled negative predictive value of 90.8% (95% confidence interval [CI] 88.1–93.1) for grade group 2 or higher cancer across 42 studies and 7321 biopsy-naive men: about nine significant cancers are missed per 100 men not biopsied. With a prostate-specific antigen (PSA) density below 0.15 ng/mL/mL as well, subsequent incidence was close to that of the general population (rate ratio 1.4, 95% CI 0.9–2.0). PI-RADS 3 lesions had a pooled positive predictive value of about 13%; density thresholds of 0.10–0.20 ng/mL/mL missed 1–14 significant cancers per 100 men spared, depending on threshold and prevalence. In screening, biopsying only MRI-positive men roughly halved overdiagnosis (relative risk 0.46, 95% CI 0.33–0.64) without a detectable rise in significant cancer, whereas omitting systematic cores in MRI-positive men reduced significant-cancer detection. Transperineal biopsy reduced infection-related admission. Biopsy can be deferred safely only when a negative or equivocal MRI is combined with a low PSA density and a defined plan of repeat PSA testing and imaging.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.